Cancer imaging

Bioxydyn provides advanced functional MRI biomarkers in oncology, using techniques such as diffusion MRI and dynamic contrast-enhanced (DCE) MRI, and is the leading CRO offering tumor hypoxia imaging to inform therapy effectiveness or characterise tumour physiology.


We are world-leading in the use of Oxygen-enhanced MRI (OE-MRI), which can be applied to monitor the delivery of oxygen to tumours. This is of particular utility, as tumour oxygenation levels are known to impact on disease progression and on response to therapy. Our method for identifying and imaging tumour hypoxia has been shown to be sensitive to drug and radiotherapy effects. Bioxydyn personnel lead the field in developing and deploying OE-MRI.

Dynamic contrast-enhanced MRI (DCE-MRI) is recognised by the Quantitative Imaging Biomarkers Alliance (QIBA) as a functional imaging biomarker of angiogenesis and vascular function in cancer. Bioxydyn personnel bring decades of experience to the study of cancer using DCE-MRI.

Diffusion MRI (apparent diffusion coefficient, ADC) detects changes in water diffusion, which is a sensitive marker for cancer. These changes are typically associated with the earliest stages of biological response to treatment and so can act as early markers of the influence of intervention.


Refererences

Little RA, Jamin Y, Boult JKR, Naish JH, Watson Y, Cheung S, Holliday KF, Lu H, McHugh DJ, Irlam J, West CML, Betts GN, Ashton G, Reynolds AR, Maddineni S, Clarke NW, Parker GJM, Waterton JC, Robinson SP, O'Connor JPB, Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology. Radiology. 2018 Sep;288(3):739-747.

O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, [...], Waterton JC, Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2017 Mar;14(3):169-186.

Little RA, Barjat H, Hare JI, Jenner M, Watson Y, Cheung S, Holliday K, Zhang W, O'Connor JPB, Barry ST, Puri S, Parker GJM, Waterton JC, Evaluation of dynamic contrast-enhanced MRI biomarkers for stratified cancer medicine: How do permeability and perfusion vary between human tumours? Magn Reson Imaging. 2018 Feb;46:98-105.

O'Connor JP, Naish JH, Parker GJ, Waterton JC, Watson Y, Jayson GC, Buonaccorsi GA, Cheung S, Buckley DL, McGrath DM, West CM, Davidson SE, Roberts C, Mills SJ, Mitchell CL, Hope L, Ton NC, Jackson A, Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1209-15.

O'Connor JPB, Robinson SP, Waterton JC, Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI. Br J Radiol. 2019 Mar;92(1095):20180642.

O'Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A, Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res. 2015 Jan 15;21(2):249-57.

Salem A, Little RA, Latif A, Featherstone AK, Babur M, Peset I, Cheung S, Watson Y, Tessyman V, Mistry H, Ashton G, Behan C, Matthews JC, Asselin MC, Bristow RG, Jackson A, Parker GJM, Faivre-Finn C, Williams KJ, O'Connor JPB, Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung Cancer. Clin Cancer Res. 2019 Jul 1;25(13):3818-3829.

Jayson GC, Zhou C, Backen A, Horsley L, Marti-Marti K, Shaw D, Mescallado N, Clamp A, Saunders MP, Valle JW, Mullamitha S, Braun M, Hasan J, McEntee D, Simpson K, Little RA, Watson Y, Cheung S, Roberts C, Ashcroft L, Manoharan P, Scherer SJ, Del Puerto O, Jackson A, O'Connor JPB, Parker GJM, Dive C, Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. Nat Commun. 2018 Nov 7;9(1):4672.

Linnik IV, Scott ML, Holliday KF, Woodhouse N, Waterton JC, O'Connor JP, Barjat H, Liess C, Ulloa J, Young H, Dive C, Hodgkinson CL, Ward T, Roberts D, Mills SJ, Thompson G, Buonaccorsi GA, Cheung S, Jackson A, Naish JH, Parker GJ, Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma. Magn Reson Med. 2014 May;71(5):1854-62.

O'Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC, Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol. 2012 Feb 14;9(3):167-77.

Leach MO, Morgan B, Tofts PS, Buckley DL, Huang W, Horsfield MA, Chenevert TL, Collins DJ, Jackson A, Lomas D, Whitcher B, Clarke L, Plummer R, Judson I, Jones R, Alonzi R, Brunner T, Koh DM, Murphy P, Waterton JC, Parker G, Graves MJ, Scheenen TW, Redpath TW, Orton M, Karczmar G, Huisman H, Barentsz J, Padhani A, Experimental Cancer Medicine Centres Imaging Network Steering Committee., Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol. 2012 Jul;22(7):1451-64.

Featherstone AK, O'Connor JPB, Little RA, Watson Y, Cheung S, Babur M, Williams KJ, Matthews JC, Parker GJM, Data-driven mapping of hypoxia-related tumor heterogeneity using DCE-MRI and OE-MRI. Magn Reson Med. 2018 Apr;79(4):2236-2245.

How can we help?

Contact us at info@bioxydyn.com